Not exact matches
Diffuse scleroderma is characterized by a lower survival rate than other forms of the disease, and no
curative pharmacological
treatment options have been
developed to - date.
Patients will be able to receive the Hutch's novel immunotherapies for cancer at roughly double the capacity that existed before the 9,222 - square - foot clinic opened, and intensive monitoring will enable researchers to better understand why some patients respond, where others do not, and to achieve the goal of
developing the best
curative approach to
treatment for each individual patient.
Nicholas P Restifo, MD, National Cancer Institute, Center for Cancer Research, «
Developing Curative Cancer
Treatments Using Adoptive Cell Transfer - Based Immunotherapies»